8 assets in Core Binding Factor Acute Myeloid Leukemia

Therapeutic assets addressing Core Binding Factor Acute Myeloid Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Core Binding Factor Acute Myeloid Leukemia	National Cancer Institute (NCI)	P2	B (57)
Daunomycin Core Binding Factor Acute Myeloid Leukemia	National Cancer Institute (NCI)	P2	B (57)
Avapritinib Core Binding Factor Acute Myeloid Leukemia	Children's Hospital of Soochow University	P2	CCC (53)
Azacitidine Core Binding Factor Acute Myeloid Leukemia	Children's Hospital of Soochow University	P2	CCC (53)
Decitabine Core Binding Factor Acute Myeloid Leukemia	Children's Hospital of Soochow University	P2	CCC (53)
Gemtuzumab Ozogamicin Core Binding Factor Acute Myeloid Leukemia	National Cancer Institute (NCI)	P2	CCC (53)
Idarubicin Core Binding Factor Acute Myeloid Leukemia	Children's Hospital of Soochow University	P2	CCC (53)
Venetoclax Core Binding Factor Acute Myeloid Leukemia	National Cancer Institute (NCI)	P2	CCC (53)